JCN Newswire Read More Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS ruth 27 5 月 2 minutes TOKYO, May 27, 2022 – (J […]
JCN Newswire Read More Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan ruth 10 5 月 4 minutes TOKYO, May 10, 2022 – (J […]
